Navigation Links
TessArae Delivers Lower Cost Option to Genetic Testing Market
Date:11/9/2009

POTOMAC FALLS, Va., Nov. 9 /PRNewswire/ -- TessArae® LLC, a global leader in resequencing microarray-based applications, announces the launch of new integrated product solutions for genetic testing of the mutations that underlie human hereditary diseases. The combination of TessArae's expertise in microarray-based resequencing with novel nucleotide sequence basecalling algorithms and analysis software enables screening for all targeted mutations in multiple genes of a syndrome or disorder simultaneously. This dramatically reduces total testing cost and time-to-result without compromising test accuracy and usability for providers of genetic testing services. The first solution, offered by GeneDx (Gaithersburg, MD), is for Noonan Syndrome, a genetic disorder that causes abnormal development of multiple parts of the body. "Implementation of the custom-designed resequencing solution from TessArae, which simultaneously detects all known mutations and screens for missense mutations in eight genes of the RAS/MAPK pathway, allows GeneDx to offer a more comprehensive test than we could previously, yet at significantly lower cost and with much faster turnaround time," states John Compton, Ph.D., Co-President and Scientific Director of GeneDx. "Based on the successful integration of this technology into our laboratory workflow, we plan to offer TessArae-developed resequencing microarray-based testing for Periodic Fever Syndromes in the immediate future." According to Klaus Schafer, M.D., MPH, President and CEO of TessArae, "The human genetic disease testing market represents a new opportunity for us. Our resequencing microarray-based solution is ideally positioned, from both a cost and time-to-result perspective, between conventional and next-gen DNA sequencing technologies, and will generate significant revenue as the genetic testing market grows."

About TessArae: TessArae's TessArray® RPM (Resequencing Pathogen Microarray) technology simultaneously detects and identifies numerous viral, bacterial, and fungal pathogens, from clinical, environmental and product samples, enabling characterization -- to the strain level -- all in a same-day, single-sample, multiple-result test. TessArae's technology is the only multiplexed genotypic technology that provides direct nucleotide sequence information from pathogen-specific genomic signatures. TessArae has several commercially available products for Research Use Only purposes, including the RPM-Flu Kit for detection and definitive identification of respiratory pathogens, the RPM-TEI Kit for tropical and emerging infections, and the RPM-HFV Kit for whole genome resequencing of HFV hemorrhagic fever viruses. TessArae is based in Potomac Falls, Loudoun County, VA just outside Washington, DC. TessArae products are not intended for in vitro diagnostic use or for patient treatment decisions.

SOURCE TessArae, LLC


'/>"/>
SOURCE TessArae, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
2. PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase II Study
3. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
4. VivoMetrics(R) Introduces Next Generation LifeShirt Prototype, a Smart Garment That Delivers Real-time Vital Signs Remotely to Healthcare Providers
5. Vtech(R) Delivers Todays Hottest Trends to Tech-Savvy Kids
6. Hoviones TwinCaps(R) Inhaler Delivers Successfully in Phase III Clinical Trials for Influenza
7. Ethicon Endo-Surgery Launches New Echelon Flex(TM) Endopath(R) Stapler That Delivers Echelon(TM) Compression, Now With Natural Articulation
8. Varian, Inc. Delivers a Productivity Increase of Up to 100% With Its 710-ES Series ICP-OES
9. Siemens Delivers Flash Speed, Lowest Dose to Arnold Palmer Hospital for Children
10. Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75
11. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2017)... , June 19, 2017  Researchers from DRUGSCAN ® ... they will host a live, complimentary webinar titled, "Untangling ... benchtop to the real world" on Wednesday June 28, ... This webinar will feature interviews with recreational ... into the manipulation techniques abusers use to prepare opioid ...
(Date:6/14/2017)... , June 14, 2017  ivWatch LLC, a ... effectiveness of intravenous (IV) therapy, is pleased to announce ... category of Nonsurgical Hospital Supplies and Equipment at the ... program for the medtech industry. The award was presented ... Jacob K. Javits Center in New York ...
(Date:6/13/2017)... , June 13, 2017 Zimmer Biomet Holdings, Inc. ... today announced that the U.S. Food and Drug Administration (FDA) ... 3, 2015 relating to its Zhejiang, China ... "The successful clearance of the Warning Letter ... manufacturing facility is a measure of the progress we have ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island Quality ... Management Alerts and Dashboards, an innovative new service enabling healthcare providers to proactively ... Management Alerts and Dashboards provide near real-time data about patients admitted to and/or ...
(Date:6/23/2017)... ... ... By scoring 100% for fiscal management and accountability, the Arthritis National Research ... Charity Navigator, validating ANRF's work as a top charity in America. , This achievement ... earns ANRF a spot on their “ 10 Charities Worth Watching ” list as ...
(Date:6/23/2017)... ... ... Studies show evidence that carotenoids and antioxidants derived either from the diet or from ... how often do ophthalmologists and optometrists in Sweden recommend the use of nutritional supplements, ... symptoms of AMD? A study published recently in Dove Medical Press journal, ...
(Date:6/23/2017)... ... June 23, 2017 , ... Dr. Ran Y. ... has recently begun offering three new minimally invasive procedures to patients who want ... reducing downtime, Dr. Rubinstein is excited to bring microneedling, microneedling facials, and platelet ...
(Date:6/23/2017)... ... 2017 , ... Everybody has their own personal preference when it comes to ... some people don't like it at all. FindaTopDoc took a look at what makes ... can give readers a taste of their deepest, darkest fantasies and has the ability ...
Breaking Medicine News(10 mins):